POZEN, Inc. (NASDAQ:POZN) has announced that it will host an investor and analyst event on Tuesday, December 8 to discuss the company’s new strategic focus and to outline the proprietary pipeline. The event will run from 7:30 am ET to 11:30 pm ET that afternoon at the NASDAQ Marketsite in New York City. Joining the event will be POZEN Chairman, President and CeO John Plachetka. The meeting will be available via webcast on the company’s website at http://www.pozen.com/.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
POZEN Inc. (POZEN), is a pharmaceutical company focused on developing products, which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain, and pain related conditions. The Company has developed Treximet (formerly known as Trexima) in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. On April 15, 2008, the United States Food and Drug Administration (FDA) approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet incorporates the Company’s MT 400 technology, which refers to its combinations of a triptan (5-HT1B/1D agonist) and a non-steroidal, anti-inflammatory drug (NSAID).
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
